a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Australia.
b ARC Centre of Excellence in Advanced Molecular Imaging, Biomedicine Discovery Institute, Department of Biochemistry , Monash University , Melbourne , Australia.
Expert Rev Hematol. 2019 Jan;12(1):5-19. doi: 10.1080/17474086.2019.1558399. Epub 2018 Dec 18.
Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule-disrupting agent monomethylauristatin E. The utility of brentuximab vedotin has been explored in a number of diseases, with a recent focus on T-cell lymphoma, particularly systemic anaplastic large-cell lymphoma (sALCL) and cutaneous T-cell lymphoma (CTCL), as well as other peripheral T-cell lymphoma (PTCL) histologies. Areas covered: This review surveys current data on the efficacy of brentuximab vedotin in T-cell lymphoma, as well as embedding it in a therapeutic context by reviewing potential competitor agents in the clinic. Data are drawn from published literature, with a focus on clinical trial data rather than preclinical studies or case reports. Expert opinion: Brentuximab vedotin has a clear clinical benefit in CTCL and sALCL, and can achieve durable responses in a number of patients. Toxicities, particularly peripheral neuropathy, may limit treatment in some patients; however, the agent is generally well tolerated. In this context, brentuximab vedotin has been globally approved for use in sALCL and certain CTCL subtypes, however, further information is required to enhance our understanding of when and in whom to best employ this agent, as well as exploring rational combinations to augment responses.
本妥昔单抗维迪昔单抗是一种抗体药物偶联物，它将一种 CD30 单克隆抗体与微管破坏剂单甲基奥瑞他汀 E 结合在一起。本妥昔单抗维迪昔单抗已在多种疾病中进行了研究，最近的重点是 T 细胞淋巴瘤，特别是系统性间变性大细胞淋巴瘤（sALCL）和皮肤 T 细胞淋巴瘤（CTCL），以及其他外周 T 细胞淋巴瘤（PTCL）组织学。
本综述调查了本妥昔单抗维迪昔单抗在 T 细胞淋巴瘤中的疗效数据，并通过回顾临床中潜在的竞争药物，将其置于治疗背景下进行评估。数据来源于已发表的文献，重点是临床试验数据，而不是临床前研究或病例报告。
本妥昔单抗维迪昔单抗在 CTCL 和 sALCL 中具有明显的临床获益，可使许多患者获得持久缓解。毒性，特别是周围神经病变，可能会限制某些患者的治疗；然而，该药物通常具有良好的耐受性。在这种情况下，本妥昔单抗维迪昔单抗已在全球范围内获准用于 sALCL 和某些 CTCL 亚型，但需要进一步的信息来增强我们对何时以及在哪些患者中最佳使用该药物的理解，以及探索合理的联合用药以增强疗效。
